Capital Advisors Ltd’s Sarepta Therapeutics SRPT Stock Holding History

Capital Advisors Ltd’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-250	Closed	-$5K	–	1586
2025 Q4	$5K	Buy	+250	New	+$5.27K	﹤0.01%	952
2023 Q1	–	Sell	-12	Closed	-$2K	–	1534
2022 Q4	$2K	Buy	12 +11	+1,100%	+$1.27K	﹤0.01%	899
2022 Q3	$0	Buy	+1	New	+$101	﹤0.01%	1501
2022 Q1	–	Sell	-2	Closed	–	–	1185
2021 Q4	$0	Buy	+2	New	+$171	﹤0.01%	926

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Advisors Ltd's SRPT Position: Q1 2026 in Review

Capital Advisors Ltd sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 250 shares — an estimated $5K sold.

Capital Advisors Ltd first reported a position in SRPT in Q4 2021 and held it in 4 quarters. The position peaked at $5K in Q4 2025. 345 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Capital Advisors Ltd reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Capital Advisors Ltd sold 250 Sarepta Therapeutics shares in Q1 2026, an estimated $5K.
Capital Advisors Ltd first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 4 quarters.
Capital Advisors Ltd's Sarepta Therapeutics position peaked at $5K in Q4 2025.
345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Capital Advisors Ltd's 13F filing for Q1 2026, filed 16 Apr 2026.